Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Annals of Oncology

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDF052PMID 11996467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dosing of thioTEPA for myeloablative therapy

  2004cited by this paper
• A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide

  2001cited by this paper
• High-dose chemotherapy in breast cancer - interpretation of the randomized trials

  2001cited by this paper
• Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

  2001cited by this paper
• Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

  2000cited by this paper
• Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens

  2000cited by this paper
• Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

  2000cited by this paper
• Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.

  2000cited by this paper
• The clinical pharmacology of alkylating agents in high-dose chemotherapy.

  2000cited by this paper
• Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.

  2000cited by this paper
• Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA).

  2000cited by this paper
• Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

  2000cited by this paper
• CONVENTIONAL-DOSE CHEMOTHERAPY COMPARED WITH HIGH-DOSE CHEMOTHERAPY PLUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR METASTATIC BREAST CANCER

  2000cited by this paper
• HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE STABILIZED CYCLOPHOSPHAMIDE METABOLITE 4-HYDROXYCYCLOPHOSPHAMIDE IN PLASMA AND RED BLOOD CELLS

  2000cited by this paper
• A search for new metabolites of N,N',N''-triethylenethiophosphoramide.

  1999cited by this paper
• A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.

  1999cited by this paper
• Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea.

  1999cited by this paper
• Sampling technique from central venous catheters proves critical for pharmacokinetic studies.

  1999cited by this paper
• Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.

  1998cited by this paper
• Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.

  1998cited by this paper
• Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

  1996cited by this paper
• Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.

  1996cited by this paper
• Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation

  1996cited by this paper
• Atlas of Surgical Oncology

  1996cited by this paper
• A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies

  1996cited by this paper
• Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.

  1996cited by this paper
• Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry

  1995cited by this paper
• The syndrome of hepatic veno-occlusive disease after marrow transplantation.

  1995cited by this paper
• High-dose chemotherapy regimens for solid tumors.

  1995cited by this paper
• Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size.

  1994cited by this paper
• Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.

  1993cited by this paper
• The importance of modeling interoccasion variability in population pharmacokinetic analyses

  1993cited by this paper
• Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.

  1992cited by this paper
• Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa.

  1992cited by this paper
• High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.

  1990cited by this paper
• A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.

  1990cited by this paper

• Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer

  2025cites this paper
• Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma

  2023cites this paper
• Influence of Renal Function on Phosphoramide Mustard Exposure: A Nonlinear Mixed‐Effects Analysis

  2022cites this paper
• Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.

  2021cites this paper
• Oral lipid nanomedicines: current status and future perspectives in cancer treatment.

  2021cites this paper
• Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy

  2021cites this paper
• Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer

  2021cites this paper
• Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced Intensity Hematopoietic Cell Transplant for Adult Hematologic Malignancy.

  2021cites this paper
• Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta‐Analysis

  2021cites this paper
• Genetic Polymorphism of GSTP-1 Affects Cyclophosphamide Treatment of Autoimmune Diseases

  2020cites this paper
• Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis

  2020cites this paper
• Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom

  2020cites this paper
• Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing

  2019cites this paper
• Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma

  2019cites this paper
• High-dose thiotepa-related neurotoxicity and the role of tramadol in children

  2018cites this paper
• Evaluation du suivi thérapeutique pharmacologique du carboplatine et étude pharmacocinétique/pharmacogénétique de l'étoposide dans le cadre d'un essai clinique de phase II d'intensification thérapeutique en cancérologie

  2018cites this paper
• Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT

  2017cites this paper
• Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma

  2016cites this paper
• The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients.

  2015cites this paper
• Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report

  2015cites this paper
• Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.

  2014cites this paper
• Chemotherapeutic Alkylating Agents in Cancer Treatment

  2013cites this paper
• BreastCare Is Routine Audiometric Evaluation Necessary in Gynaecologic Tumour Patients Undergoing Chemotherapy ?

  2013cites this paper
• Is Routine Audiometric Evaluation Necessary in Gynaecologic Tumour Patients Undergoing Chemotherapy?

  2013cites this paper
• Portal Vein Thrombosis in non cirrhotic patients

  2010cites this paper
• Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

  2009influential citation
• Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

  2009cites this paper
• Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin

  2008cites this paper
• Pharmacogenetics and Pharmacokinetics in high-dose alkylating chemotherapy

  2008cites this paper
• Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency

  2008cites this paper
• Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans

  2008cites this paper
• Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

  2008cites this paper
• Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology

  2008cites this paper
• Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours

  2007cites this paper
• Cancer chemotherapy II: atypical hepatic injuries.

  2007cites this paper
• Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.

  2007cites this paper
• High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

  2006influential citation
• Dose Individualization of Carboplatin After a 120-hour Infusion Schedule: Higher Dose Intensity but Fewer Toxicities

  2006cites this paper
• Pharmakokinetik, Pharmakodynamik und intrazelluläre Kinetik

  2006cites this paper
• Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function

  2006cites this paper
• Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes

  2005cites this paper
• Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy

  2005influential citation
• An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.

  2005cites this paper
• Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

  2005cites this paper
• Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin

  2005cites this paper
• Metabolism‐based cyclophosphamide dosing for hematopoietic cell transplant

  2005cites this paper
• Primary prevention with over‐the‐counter statins: A cautionary tale

  2005cites this paper
• L-Carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC)

  2005cites this paper
• Sparse Sampling Design for Therapeutic Drug Monitoring of Sequentially Administered Cyclophosphamide, Thiotepa, and Carboplatin (CTC)

  2005cites this paper
• Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  2004cites this paper
• Integrated Population Pharmacokinetic Model of Both Cyclophosphamide and Thiotepa Suggesting a Mutual Drug–Drug Interaction

  2004cites this paper
• Mini review Pharmacokinetics of high-dose chemotherapy

  2004cites this paper
• Pharmacokinetics of high-dose chemotherapy

  2004cites this paper
• Pharmacokinetically guided dosing of (high-dose) chemotherapeutic agents

  2004cites this paper
• Ototoxicity in patients with dose-intensive therapy for cisplatin-resistant germ cell tumors.

  2004cites this paper
• Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience

  2003cites this paper
• DNA-binding agents.

  2003cites this paper
• Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer

  2003cites this paper
• DNA-binding agents.

  2002cites this paper
• Is pharmacokinetically guided chemotherapy dosage a better way forward?

  2002cites this paper
• Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin

  2002cites this paper
• Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy

  2002cites this paper
• Clinical Pharmacokinetics of Cyclophosphamide

  1979cites this paper